There are more innovative medicines than ever being developed across the globe, yet many people can't access them. We refer to this as “the healthcare paradox.”
We dare to change that.
Patient access to cancer medicines vary widely between countries. For example, in the European Union4,5:
Learn about our mission to deliver innovative medicines that are available,
accessible, and affordable to anyone, anywhere in the world.
References: 1. Proctor P. A new approach to eliminating health disparities. https://www.rwjf.org/en/blog/2015/02/let_s_eliminate_heal.html. Accessed March 2, 2022. 2. Szabo L. As drug costs soar, people delay or skip cancer treatments. https://www.npr.org/sections/health-shots/2017/03/15/520110742/as-drug-costs-soar-people-delay-or-skip-cancer-treatments. Published March 15, 2017. Accessed March 2, 2022. 3. Data on file. Luzsana Biotechnology, 2022. 4. Jansen C, Amesz. Every day counts: improving time to patient access to innovative oncology therapies in Europe. July 2020. 5. Cortes J, Perez-Garcia J, Llombart-Cussac A, et al. Enhancing global access to cancer medicines. CA Cancer J Clin. 2020;70(2):105-124. 6. Fundytus A, Sengar M, Lombe D, et al. Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey. Lancet Oncol. 2021;22:1367-1377. 7. Kullgren JT, McLaughlin CG, Mitra N, Armstrong K. Nonfinancial barriers and access to care for US adults. Health Serv Res. 2012;47(1):462-485.